Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

210 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Papillary thyroid cancer: monitoring and therapy.
Tuttle RM, Leboeuf R, Martorella AJ. Tuttle RM, et al. Endocrinol Metab Clin North Am. 2007 Sep;36(3):753-78, vii. doi: 10.1016/j.ecl.2007.04.004. Endocrinol Metab Clin North Am. 2007. PMID: 17673127 Review.
Medical management of thyroid cancer: a risk adapted approach.
Tuttle RM, Leboeuf R, Shaha AR. Tuttle RM, et al. J Surg Oncol. 2008 Jun 15;97(8):712-6. doi: 10.1002/jso.21010. J Surg Oncol. 2008. PMID: 18493922 Review.
Follow up approaches in thyroid cancer: a risk adapted paradigm.
Tuttle RM, Leboeuf R. Tuttle RM, et al. Endocrinol Metab Clin North Am. 2008 Jun;37(2):419-35, ix-x. doi: 10.1016/j.ecl.2008.02.008. Endocrinol Metab Clin North Am. 2008. PMID: 18502335 Review.
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA. Ho AL, et al. N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288. N Engl J Med. 2013. PMID: 23406027 Free PMC article. Clinical Trial.
Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system.
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Tuttle RM, et al. Thyroid. 2010 Dec;20(12):1341-9. doi: 10.1089/thy.2010.0178. Epub 2010 Oct 29. Thyroid. 2010. PMID: 21034228 Free PMC article.
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. Leboeuf R, et al. J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1. J Clin Endocrinol Metab. 2008. PMID: 18381570 Free PMC article.
Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications.
Ghossein RA, Leboeuf R, Patel KN, Rivera M, Katabi N, Carlson DL, Tallini G, Shaha A, Singh B, Tuttle RM. Ghossein RA, et al. Thyroid. 2007 Jul;17(7):655-61. doi: 10.1089/thy.2007.0061. Thyroid. 2007. PMID: 17696836
"Hook effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature.
Leboeuf R, Langlois MF, Martin M, Ahnadi CE, Fink GD. Leboeuf R, et al. J Clin Endocrinol Metab. 2006 Feb;91(2):361-4. doi: 10.1210/jc.2005-1429. Epub 2005 Nov 8. J Clin Endocrinol Metab. 2006. PMID: 16278263
210 results
Jump to page
Feedback